These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 21726252)

  • 1. IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin.
    Giannini EG; Marenco S; Baldissarro I; Fazio V
    Aliment Pharmacol Ther; 2011 Aug; 34(3):398-400. PubMed ID: 21726252
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancing predictive ability of IL28B-SNPs for SVR in HCV.
    Amanzada A; Schneider S; Moriconi F; Mihm S; van Thiel DH; Ramadori G
    Aliment Pharmacol Ther; 2012 Jan; 35(2):317-8. PubMed ID: 22172087
    [No Abstract]   [Full Text] [Related]  

  • 3. Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2011 Jul; 34(1):102-3. PubMed ID: 21631552
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: the ss469415590 SNP--an IL28B marker looking for a home.
    Congly SE; Lee SS
    Aliment Pharmacol Ther; 2014 Feb; 39(3):339. PubMed ID: 24397320
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin-28B rs12979860 haplotype.
    Albert ML; Casrouge A; Chevaliez S; Hézode C; Rosa I; Renard P; Mallet V; Fontanet A; Pawlotsky JM; Pol S
    Hepatology; 2011 Apr; 53(4):1410-1. PubMed ID: 21480356
    [No Abstract]   [Full Text] [Related]  

  • 6. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.
    Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
    Gut; 2012 Nov; 61(11):1640-1. PubMed ID: 22345656
    [No Abstract]   [Full Text] [Related]  

  • 7. Lost in translation? IL28B's discovery and the journey back to the patient.
    Clark PJ; Muir AJ
    Hepatology; 2012 Jul; 56(1):5-8. PubMed ID: 22511499
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C.
    Stättermayer AF; Hofer H; Ferenci P
    J Hepatol; 2012 Sep; 57(3):706; author reply 706-7. PubMed ID: 22748774
    [No Abstract]   [Full Text] [Related]  

  • 9. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
    Thompson AJ; McHutchison JG
    Hepatology; 2012 Jul; 56(1):373-81. PubMed ID: 22511355
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection and HCV Extrahepatic Manifestations.
    Antonelli A; Pistello M
    Curr Drug Targets; 2017; 18(7):752-755. PubMed ID: 26521772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR.
    Jafferbhoy H; Miller MH; El Wahed Z; Dillon JF
    J Hepatol; 2011 Nov; 55(5):1162-4; author reply 1164-6. PubMed ID: 21740939
    [No Abstract]   [Full Text] [Related]  

  • 12. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
    Eslam M; George J
    Hepatol Int; 2015 Jan; 9(1):5-8. PubMed ID: 25788373
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.
    Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM
    Aliment Pharmacol Ther; 2014 Feb; 39(3):343. PubMed ID: 24397325
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C--authors' reply.
    Stättermayer AF; Ferenci P
    Aliment Pharmacol Ther; 2014 Feb; 39(3):344. PubMed ID: 24397327
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.
    Lin JC; Habersetzer F; Rodriguez-Torres M; Afdhal N; Lawitz EJ; Paulson MS; Zhu Y; Subramanian GM; McHutchison JG; Sulkowski M; Wyles DL; Schooley RT
    J Infect Dis; 2014 Dec; 210(12):1881-5. PubMed ID: 24907384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral genotypes and human rs12979860 polymorphism of the IFNL3 gene in hepatitis C infected patients in Southern Brazil.
    Frizon K; Alves CF; Borchardt AC; Lunge VR; Simon D
    Braz J Infect Dis; 2014; 18(2):229-30. PubMed ID: 24389274
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hepatitis C at a crossroads].
    Moradpour D; Dorta G
    Rev Med Suisse; 2010 Jan; 6(233):163-4. PubMed ID: 20214186
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relation of IL28B gene polymorphism to chronic hepatitis C].
    Matsuura K; Tanaka Y
    Nihon Rinsho; 2011 May; 69 Suppl 4():227-33. PubMed ID: 22096924
    [No Abstract]   [Full Text] [Related]  

  • 19. A watershed moment in the treatment of hepatitis C.
    Chung RT
    N Engl J Med; 2012 Jan; 366(3):273-5. PubMed ID: 22256811
    [No Abstract]   [Full Text] [Related]  

  • 20. Micromanaging hepatitis C virus.
    Lieberman J; Sarnow P
    N Engl J Med; 2013 May; 368(18):1741-3. PubMed ID: 23534545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.